114 related articles for article (PubMed ID: 30717079)
1. The association between new inflammation markers and frequent peritoneal dialysis-associated peritonitis.
Tang J; Wang D; Chen Y; Feng J
BMC Nephrol; 2024 Mar; 25(1):81. PubMed ID: 38443857
[TBL] [Abstract][Full Text] [Related]
2. Combinative predictive effect of left ventricular mass index, ratio of HDL and CRP for progression of chronic kidney disease in non-dialysis patient.
Tang L; Li S; Guo X; Lai J; Liu P; Fang J; Liu X
Int Urol Nephrol; 2024 Jan; 56(1):205-215. PubMed ID: 37204678
[TBL] [Abstract][Full Text] [Related]
3. Enhancing Immune Protection in Hemodialysis Patients: Role of the Polymethyl Methacrylate Membrane.
Franzin R; Stasi A; Caggiano G; Squiccimarro E; Losappio V; Fiorentino M; Alfieri C; Stallone G; Gesualdo L; Castellano G
Blood Purif; 2023 Apr; 52(Suppl 1):1-13. PubMed ID: 37075738
[TBL] [Abstract][Full Text] [Related]
4. COVID-19 Vaccination in Kidney Transplant Candidates and Recipients.
Ponticelli C; Campise M
Vaccines (Basel); 2022 Oct; 10(11):. PubMed ID: 36366317
[TBL] [Abstract][Full Text] [Related]
5. HDL Composition, Heart Failure, and Its Comorbidities.
Diab A; Valenzuela Ripoll C; Guo Z; Javaheri A
Front Cardiovasc Med; 2022; 9():846990. PubMed ID: 35350538
[TBL] [Abstract][Full Text] [Related]
6. Subpopulations of High-Density Lipoprotein: Friends or Foes in Cardiovascular Disease Risk in Chronic Kidney Disease?
Coimbra S; Reis F; Valente MJ; Rocha S; Catarino C; Rocha-Pereira P; Sameiro-Faria M; Bronze-da-Rocha E; Belo L; Santos-Silva A
Biomedicines; 2021 May; 9(5):. PubMed ID: 34065648
[TBL] [Abstract][Full Text] [Related]
7. Current Understanding of the Immunomodulatory Activities of High-Density Lipoproteins.
Trakaki A; Marsche G
Biomedicines; 2021 May; 9(6):. PubMed ID: 34064071
[TBL] [Abstract][Full Text] [Related]
8. Immune Dysfunction in Uremia 2020.
Cohen G
Toxins (Basel); 2020 Jul; 12(7):. PubMed ID: 32635646
[TBL] [Abstract][Full Text] [Related]
9. Immune dysfunction in uremia.
Cohen G; Haag-Weber M; Hörl WH
Kidney Int Suppl; 1997 Nov; 62():S79-82. PubMed ID: 9350688
[TBL] [Abstract][Full Text] [Related]
10. Dysfunction of polymorphonuclear leukocytes in uremia.
Haag-Weber M; Hörl WH
Semin Nephrol; 1996 May; 16(3):192-201. PubMed ID: 8734462
[TBL] [Abstract][Full Text] [Related]
11. High-Density Lipoprotein from Chronic Kidney Disease Patients Modulates Polymorphonuclear Leukocytes.
Raupachova J; Kopecky C; Cohen G
Toxins (Basel); 2019 Feb; 11(2):. PubMed ID: 30717079
[TBL] [Abstract][Full Text] [Related]
12. Effect of High-Density Lipoprotein from Healthy Subjects and Chronic Kidney Disease Patients on the CD14 Expression on Polymorphonuclear Leukocytes.
Cohen G
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33799511
[TBL] [Abstract][Full Text] [Related]
13. The uraemic toxin phenylacetic acid contributes to inflammation by priming polymorphonuclear leucocytes.
Cohen G; Raupachova J; Hörl WH
Nephrol Dial Transplant; 2013 Feb; 28(2):421-9. PubMed ID: 23229930
[TBL] [Abstract][Full Text] [Related]
14. The uraemic retention solute para-hydroxy-hippuric acid attenuates apoptosis of polymorphonuclear leukocytes from healthy subjects but not from haemodialysis patients.
Cohen G; Raupachova J; Wimmer T; Deicher R; Hörl WH
Nephrol Dial Transplant; 2008 Aug; 23(8):2512-9. PubMed ID: 18319358
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
